THE GLOBAL THREAT OF TYPE 2 DIABETES
The 21st century has the most diabetogenic environment in human history [2, 3] . Over the past 25 years or so, the prevalence of type 2 diabetes in the USA has almost doubled, with three-to five-fold increases in India, Indonesia, China, Korea and Thailand [4] . In 2007, there were 246 million people with diabetes in the world, but by 2025, that number is estimated to reach 380 million [5] . People with impaired glucose tolerance, a "prediabetic state" numbered 308 million in 2007 and will increase to 418 million by 2025 [5] . The increase in prevalence of diabetes will be greater in the developing countries. In Mexico for example, 18% of its adult population will have with type 2 diabetes by 2025. According to the WHO, China and India will have about 130 million diabetics by 2025 who will consume about 40% of their country's healthcare budget in addition to reducing productivity and hindering economic growth.
It was against this background that on December 21 st 2006, the United Nations General Assembly unanimously passed Resolution 61/225 declaring diabetes an international public health issue and identifying World Diabetes Day as a United Nations Day, only the second disease after HIV/AIDS to attain that status. For the first time, governments have acknowledged that a non-infectious disease poses as serious a threat to world health as infectious diseases like HIV/AIDS, tuberculosis and malaria. The problems of diabetes are now seen as a major global public health concern, especially in the developing world which can least afford it. The first step to act on diabetic kidney disease must encompass public health campaigns aimed at preventing the development of type 2 diabetes.
DIABETIC KIDNEY DISEASE
Diabetes is now the major cause of end stage kidney failure throughout the world in both developed and emerging nations [6] . It is the primary diagnosis causing kidney disease in 20-40% of people starting treatment for end stage renal disease worldwide [7] . In Australia, new type 2 diabetes patients starting dialysis increased 5-fold between 1993 and 2007 [8] . Between 1983 and 2005, there was a 7-fold increase in new patients starting renal replacement therapy in Japan because of diabetes, accounting for 40% of all new incidence patients [9] . Thus, some 30% of the predicted 1.1 trillion dollar medical costs of dialysis worldwide during this decade will result from diabetic nephropathy [10] .
In the United Kingdom Prospective Diabetes Study (UKPDS), the rates of progression of newly diagnosed type 2 diabetics between the stages of normoalbuminuria, microalbuminuria, macroalbuminuria and renal failure were 2-3% per year [11] . Over a median of 15 years of follow-up of 4,000 participants, almost 40% developed microalbuminuria [12] . In the DEMAND study of 32,208 people from 33 countries with known type 2 diabetes attending their family doctor, 39% had microalbuminuria and prevalence increased with age, duration of diabetes and presence of hypertension [13] ). About 30% of the UKPDS cohort developed renal impairment, of which almost 50% did not have preceding albuminuria [12] . Reduced glomerular filtration rate and albuminuria caused by diabetic nephropathy are independent risk factors for cardiovascular events and death [14] . Therefore, a strategy to detect early diabetic kidney disease by screening for albuminuria as well as reduced glomerular filtration rate is the second step in taking action on diabetic kidney disease.
An added difficulty to overcome is the remarkable lack of awareness among patients about their condition. In population-based surveys, for every known diabetic patient, there is at least one more that is unknown [15] ; only 8.7% of the general population were able to identify diabetes as a risk factor for kidney disease [16] . For patients with diabetic kidney disease, very few are aware of their condition with some community surveys putting patient awareness of their disease as low as 9.4%, particularly in those with milder impairment [17] . Thus, public education is the third step required for acting on diabetic kidney disease in the community. The IFKF has a long term goal for all kidney patients world-wide to not only be aware of their disease, but to actively know for example their blood pressure and the treatment objectives.
MANAGEMENT OF DIABETIC KIDNEY DISEASE
There is little use in screening populations or "at risk" groups unless follow up is undertaken and effective treatment is begun and assessed [18] . Fortunately, there is evidence that early therapeutic intervention in patients with chronic kidney disease or diabetes can delay onset of complications and improve outcomes. For example, the UKPDS [19, 20] , STENO-2 [21] , and ADVANCE studies [22] [23] [24] all demonstrated that tight control of blood glucose level, blood pressure (and lipids in STENO-2) significantly reduced incidence and progression of diabetic kidney disease. In people with type 2 diabetes, inhibition of the renin-angiotensin-aldosterone system using an ACE inhibitor or an ARB decreased the progression from normoalbuminuria to microalbuminuria [25] , reduced the progression from micro albuminuria to macroalbuminuria [26] , and slowed the development of ESRD [27] . Thus the use of an ACE inhibitor or ARB is now standard therapy for patients with diabetic nephropathy as well as glucose, lipid and blood pressure control. Effective management using evidence-based therapies is the fourth step in tackling diabetic kidney disease.
The fifth step is development of new therapies. Many new agents are now in clinical trials to reduce renal damage and fibrosis, including blockade of formation of advanced glycation endproducts and other signalling pathways. Other novel agents may potentially prove to be effective in large randomised double-blind clinical trials [28] .
HOW CAN WE ACT NOW?
The steps to be taken are clear: campaigns aimed at (1) prevention of type 2 diabetes; (2) screening for early diabetic kidney disease; (3) increasing patient awareness of kidney disease; (4) using medications of proven strategy and finally (5) researching and trialling of new therapies. The ultimate challenge is to get action from primary health care to all higher levels; from the individual patient, to those at risk, in various health jurisdictions, in all countries despite varying economic circumstances and priorities. The problem is a global one and yet requires action at a local level; prevention screening and treatment strategies; education, including increasing awareness both in diabetic patients and those at risk of developing diabetes; and health priorities and governments. Basic research and clinical trials searching for a new understanding and therapies must be supported. 
